EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieLeserbriefOpen Access · CC BY-NC-ND 4.0

Long‐term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open‐label extension study following a phase 3 placebo‐controlled, double‐blind, parallel‐group study

Masataka Kuwana iD, Tomoki Ito iD, Shugo Kowata iD, Yoshihiro Hatta iD, Katsumichi Fujimaki iD, Kensuke Naito, Shingo Kurahashi, Toshiya Kagoo iD, Kazuki Tanimoto, So Saotome, Yoshiaki Tomiyama iD

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27176 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Masataka Kuwana und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Japan. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Aminopyridines, Morpholines, Pyrimidines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kissei Pharmaceutical Co., Ltd., Kissei.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombocytopenic, IdiopathicAminopyridinesMorpholinesPyrimidinesHumansJapanPyridinesOxazinesDouble-Blind MethodTreatment Outcome

Substanzen

fostamatinibPyridinesOxazinesAminopyridinesMorpholinesPyrimidines

Autor:innen und Institutionen

  • Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Japan.
  • First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
  • Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.
  • Department of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan.
  • Department of Hematology, Fujisawa City Hospital, Fujisawa, Japan.
  • Department of Hematology, Hamamatsu Medical Center, Hamamatsu, Japan.

ORCID-Profile: Masataka Kuwana, Tomoki Ito, Shugo Kowata, Yoshihiro Hatta, Katsumichi Fujimaki, Toshiya Kagoo, Yoshiaki Tomiyama

Förderung

  • Kissei Pharmaceutical Co., Ltd.
  • Kissei

Zitieren

APA

Kuwana, M., Ito, T., Kowata, S., Hatta, Y., Fujimaki, K., Naito, K., Kurahashi, S., Kagoo, T., Tanimoto, K., Saotome, S., & Tomiyama, Y. (2024). Long‐term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open‐label extension study following a phase 3 placebo‐controlled, double‐blind, parallel‐group study. American Journal of Hematology. https://doi.org/10.1002/ajh.27176

Vancouver

Kuwana M, Ito T, Kowata S, Hatta Y, Fujimaki K, Naito K, et al. Long‐term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open‐label extension study following a phase 3 placebo‐controlled, double‐blind, parallel‐group study. American Journal of Hematology. 2024. doi:10.1002/ajh.27176

BibTeX
@article{Kuwana2024,
  author = {Kuwana, Masataka and Ito, Tomoki and Kowata, Shugo and Hatta, Yoshihiro and Fujimaki, Katsumichi and Naito, Kensuke and Kurahashi, Shingo and Kagoo, Toshiya and Tanimoto, Kazuki and Saotome, So and Tomiyama, Yoshiaki},
  title = {Long‐term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open‐label extension study following a phase 3 placebo‐controlled, double‐blind, parallel‐group study},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27176}
}
Kostenlos starten →